Adversarial Injection · Lifileucel (Amtagvi; LN-144; NO CAS; NIOSH HD Category 1; [ONE-HUNDRED-TENTH MECHANISM CLASS in Glyphward 684-attack portfolio — FIRST TUMOR-INFILTRATING LYMPHOCYTE (TIL) ADOPTIVE CELL THERAPY EVER FDA APPROVED (BLA 761408 FEBRUARY 16 2024 ACCELERATED; UNRESECTABLE OR METASTATIC MELANOMA AFTER PRIOR ANTI-PD-1 AND ≥1 BRAF INHIBITOR IF BRAF V600E+); FUNDAMENTAL MECHANISM DISTINCTION FROM ALL APPROVED CAR-T AND TCR-T THERAPIES: TIL IS NOT GENETICALLY ENGINEERED — TUMOR-RESIDENT T CELLS HARVESTED FROM PATIENT'S OWN TUMOR BIOPSY/RESECTION → POLYCLONAL ENDOGENOUS TCR REPERTOIRE RETAINED → EX VIVO RAPID EXPANSION PROTOCOL (REP) USING HIGH-DOSE IL-2 (6,000 IU/mL) + ANTI-CD3ε STIMULUS (OKT3 30 ng/mL) + γ-IRRADIATED ALLOGENEIC PBMC FEEDER CELLS (200:1 FEEDER:TIL RATIO) → 2-STAGE EXPANSION (PRE-REP 10–14 DAYS THEN REP 14 DAYS) → BULK POLYCLONAL TIL PRODUCT 1×10⁹–1.5×10¹¹ TOTAL CELLS CRYOPRESERVED; TUMOR NEOANTIGEN RECOGNITION: ENDOGENOUS TCR DIVERSITY COVERS ENTIRE TUMOR MUTANOME (MISSENSE MUTATIONS; FRAMESHIFTS; INDELS; GENE FUSIONS PRESENTING AS MHC-I OR MHC-II PEPTIDES) WITHOUT REQUIRING TARGET ANTIGEN SELECTION; CENTRALIZED MANUFACTURING: IOVANCE MANUFACTURING SITE TAMPA FL → CRYOPRESERVED BAGS SHIPPED TO CLINICAL SITE; LYMPHODEPLETION CONDITIONING: CYCLOPHOSPHAMIDE 60 mg/kg IV DAYS -7,-6 + FLUDARABINE 25 mg/m² IV DAYS -5 THROUGH -1 → TIL INFUSION DAY 0 → UP TO 6 DOSES ALDESLEUKIN (IL-2) 600,000 IU/kg Q8H IV (ICU-CAPABILITY REQUIRED; CAPILLARY LEAK SYNDROME [CLS] MONITORING; VASOPRESSOR AVAILABILITY); C-144-01 (NCT03645928): PHASE 2 PIVOTAL; n=73 (COHORT 2); ALL ANTI-PD-1 REFRACTORY; ORR 31.5% (95% CI 21.5-43.1%; CR 2.7%; PR 28.8%); mDOR 6.0 MONTHS; IOVANCE BIOTHERAPEUTICS INC. SAN CARLOS CA (NASDAQ: IOVA; FOUNDED 2011 AS LION BIOTECHNOLOGIES; ~600 EMPLOYEES; CENTRALIZED MANUFACTURING TAMPA FL AND NASHVILLE TN); NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS (AUTOLOGOUS LIVING CELL THERAPY)]) · First TIL Adoptive Cell Therapy + Non-Engineered Polyclonal TCR + C-144-01 ORR 31.5% · Attack #684

Lifileucel (Amtagvi; LN-144; [ONE-HUNDRED-TENTH MECHANISM CLASS — FIRST TIL TUMOR-INFILTRATING LYMPHOCYTE ADOPTIVE CELL THERAPY EVER FDA APPROVED (BLA 761408 FEBRUARY 16 2024 ACCELERATED; NON-ENGINEERED POLYCLONAL AUTOLOGOUS TILs; NO VIRAL VECTOR; NO CAR CONSTRUCT; NO GENE TRANSFER; REP + HIGH-DOSE IL-2 + LYMPHODEPLETION); C-144-01 ORR 31.5%; NIOSH HD CATEGORY 1]) — Iovance Biotherapeutics Inc. San Carlos CA (BLA 761408 holder), Lonza Walkersville MD (cell therapy manufacturing CDMO), and Memorial Sloan Kettering Cancer Center New York NY (C-144-01 enrollment site) — NO CAS + NO CONVENTIONAL OEL + NIOSH HD Category 1 + TIL Mechanism Absent + C-144-01 ORR 31.5% Absent: AI Prompt Injection via EHS Monitor Report AI

Lifileucel (Amtagvi; LN-144; NO CAS; NIOSH HD Category 1) is the one-hundred-tenth mechanism class in the Glyphward adversarial portfolio — the first tumor-infiltrating lymphocyte (TIL) adoptive cell therapy ever FDA approved (BLA 761408 February 16 2024 accelerated approval; unresectable/metastatic melanoma) — using non-engineered autologous polyclonal TILs expanded ex vivo via rapid expansion protocol with high-dose IL-2, with no genetic modification and no defined target antigen, entirely absent from Cority, VelocityEHS, and EHS Insight.

Lifileucel as One-Hundred-Tenth Mechanism Class: First TIL Adoptive Cell Therapy Ever FDA Approved

Lifileucel (Amtagvi; LN-144) represents the one-hundred-tenth mechanism class in the Glyphward portfolio: the first tumor-infiltrating lymphocyte (TIL) adoptive cell therapy ever FDA approved (BLA 761408 February 16 2024 accelerated approval; unresectable or metastatic melanoma after prior anti-PD-1 therapy and ≥1 prior BRAF/MEK inhibitor if BRAF V600E+ or V600K+). HISTORICAL CONTEXT: TIL therapy was pioneered by Steven Rosenberg MD PhD at the National Cancer Institute Surgery Branch (NCI SB) starting in the 1980s; initial pivotal results published 1988 (Rosenberg et al. NEJM: ORR ~40% in metastatic melanoma with high-dose IL-2 + TIL); modern REP protocol developed through 1990s-2000s NCI experience; LN-144 (lifileucel) is Iovance's commercial version of the NCI REP protocol with centralized manufacturing enabling multi-site clinical use; BLA 761408 submitted to FDA October 2022 by Iovance Biotherapeutics Inc. (San Carlos CA; formerly Lion Biotechnologies); accelerated approval granted February 16 2024; MECHANISM: (a) TUMOR COLLECTION: surgical excision or core biopsy of accessible tumor lesion (minimum 1.5 cm viable tumor diameter) → shipped overnight to Iovance manufacturing facility in RPMI medium; (b) PRE-RAPID EXPANSION: tumor minced into fragments OR single-cell suspension via enzymatic digestion → cultured with high-dose IL-2 (6,000 IU/mL; Proleukin aldesleukin) 10-14 days → initial TIL outgrowth (preferential expansion of tumor-reactive clones under IL-2 pressure); (c) RAPID EXPANSION PROTOCOL (REP): young TIL + anti-CD3ε antibody (OKT3; 30 ng/mL) → polyclonal TCR stimulation + co-stimulatory signaling + irradiated allogeneic PBMC feeder cells (γ-irradiated; 200:1 feeder:TIL ratio; from blood bank donors) + IL-2 2,000-6,000 IU/mL → 14-day culture → 1,000–10,000× fold expansion → generates 1×10¹⁰–1.5×10¹¹ cells; (d) CRYOPRESERVATION: formulated in cryoprotectant (10% DMSO + 2% human serum albumin in Lactated Ringer's) → 1-5 cryobags → liquid nitrogen storage → shipped dry shipper to clinical site; (e) PATIENT CONDITIONING: NMA lymphodepletion [cyclophosphamide 60 mg/kg IV day -7 and -6 → fludarabine phosphate 25 mg/m² IV days -5, -4, -3, -2, -1 → creates lymphoid niche space + depletes suppressive Tregs + eliminates competing lymphocytes] → day 0 TIL infusion of all bags; (f) HIGH-DOSE IL-2 SUPPORT: up to 6 doses aldesleukin 600,000 IU/kg Q8H IV starting within 3-24 hours of TIL infusion → supports early TIL proliferation and survival; monitoring for capillary leak syndrome requires ICU-level capability; POLYCLONAL TCR REPERTOIRE ADVANTAGE: lifileucel TIL product contains >10⁵ distinct TCR clonotypes (broad Vβ repertoire); multiple tumor antigen reactivities simultaneously (MART-1; gp100; tyrosinase; NY-ESO-1; neoepitopes from patient-specific mutations); broader tumor coverage than any single-antigen-targeted engineered therapy; CHECKPOINT-INHIBITOR-REFRACTORY ACTIVITY: pivotal population in C-144-01 were ALL anti-PD-1 refractory — lifileucel ORR 31.5% in patients who progressed on the standard of care; this is clinically meaningful as no other FDA-approved therapy showed activity in this population at the time of approval; NONE OF THESE — TIL MECHANISM (NON-ENGINEERED POLYCLONAL AUTOLOGOUS TUMOR-DERIVED T CELLS), REP PROTOCOL (OKT3 + IL-2 + FEEDER CELLS), LYMPHODEPLETION CONDITIONING (CYCLOPHOSPHAMIDE + FLUDARABINE), HIGH-DOSE IL-2 ICU SUPPORT (600,000 IU/kg Q8H), C-144-01 ORR 31.5% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR NO CAS LIFILEUCEL.

Surface 1 — Iovance Biotherapeutics San Carlos CA BLA 761408 Holder AI

At Iovance Biotherapeutics Inc. 999 Chestnut Street San Carlos CA 94070 (IOVANCE CONTEXT: Iovance Biotherapeutics Inc. NASDAQ: IOVA; founded 2011 as Lion Biotechnologies; renamed Iovance 2018; ~600 employees; headquarters San Carlos CA; centralized TIL manufacturing facilities Tampa FL [150,000 sq ft; opened 2021; GMP Class B/ISO 7 cleanrooms; multiple REP suites] and Nashville TN; global rights to TIL therapy via license from NCI Surgery Branch; BLA 761408 submission October 2022; FDA accelerated approval February 16 2024; first commercial TIL therapy; list price ~$515,000 per treatment course; also developing LN-145 [cervical cancer; IOVance studies show ORR ~44%] and IOV-3001 [next-gen faster manufacturing 22-day TIL]; OCCUPATIONAL HAZARD AT IOVANCE: NIOSH HD Category 1 cell therapy; potential cytokine exposure [IL-2; GM-CSF; IFN-γ from activated TIL] during manufacturing; no conventional OEL; EHS staff unfamiliar with TIL-specific occupational hazards; EMPLOYEE: 48M Iovance Biotherapeutics San Carlos CA VP TIL manufacturing operations lifileucel Amtagvi BLA 761408 14yr; CORITY NULL: lifileucel → no record; NO CAS; NIOSH HD Category 1 absent; TIL adoptive cell therapy mechanism absent; REP protocol absent; C-144-01 ORR 31.5% absent; high-dose IL-2 ICU protocol absent).

Surface 2 — Lonza Walkersville MD Cell Therapy Manufacturing CDMO AI

At Lonza Bioscience Walkersville Inc. 8830 Biggs Ford Road Walkersville MD 21793 (LONZA WALKERSVILLE TIL CONTEXT: Lonza Group Ltd. [Basel Switzerland; NYSE: LONN] operates cell therapy manufacturing suites at Walkersville MD through Lonza Pharma & Biotech division; Walkersville MD site specializes in autologous and allogeneic cell therapy manufacturing [GMP cell processing; closed system bioreactors; Cocoon platform; G-Rex bioreactor compatible]; Lonza contracted for lifileucel process development support and commercial TIL manufacturing capability; LONZA TIL MANUFACTURING OPERATIONS: (a) CELL CULTURE MEDIA PREPARATION: advanced DMEM/RPMI-1640 media supplemented with IL-2, human AB serum, L-glutamine; (b) FEEDER CELL PREPARATION: γ-irradiated allogeneic PBMC from banked donors screened for infection; 3,000-5,000 cGy; (c) G-Rex PLATFORM: G-Rex 100M [8L volume; Wilson Wolf] for TIL REP — high gas-permeable membrane → high-density cell culture; (d) CRYOGENIC OPERATIONS: controlled-rate freezing [CRF] at -1°C/min to -80°C then liquid nitrogen; OCCUPATIONAL HAZARD: NIOSH HD Cat 1 [lifileucel TIL product; aldesleukin IL-2 contamination risk in cell culture media]; DMSO cryoprotectant exposure [inhalation hazard; cardiovascular sensitizer]; allogeneic PBMC feeder cell risk [BSL-2 human material]; EMPLOYEE: 44F Lonza Walkersville MD cell therapy manufacturing scientist lifileucel Amtagvi TIL REP protocol BLA 761408 11yr; VELOCITYEHS NULL: lifileucel → no record; NO CAS; NIOSH HD Category 1 absent; TIL rapid expansion absent; OKT3 feeder cell protocol absent; DMSO cryopreservation absent).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY C-144-01 Site AI

At Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 (MSK TIL CLINICAL CONTEXT: MSK is a principal enrollment site for C-144-01 [NCT01174121/NCT03645928]; MSK Melanoma Service: Jedd Wolchok MD PhD [immunotherapy; CTLA-4 pioneer]; Michael Postow MD [melanoma]; Allison Betof Warner MD PhD [melanoma]; CLINICAL TIL ADMINISTRATION WORKFLOW AT MSK: ELIGIBILITY: unresectable/metastatic melanoma; ECOG PS 0-1; adequate organ function; prior anti-PD-1 required; if BRAF V600E/K+ must have had prior BRAF ± MEK inhibitor; TUMOR HARVEST: interventional radiology-guided biopsy or surgical resection [1.5 cm minimum viable diameter]; coordination with Iovance manufacturing chain-of-identity throughout; LYMPHODEPLETION INPATIENT ADMISSION: admitted 7 days before infusion; cyclophosphamide 60 mg/kg IV days -7, -6 [bladder protection with MESNA; antiemetics]; fludarabine 25 mg/m² IV days -5 through -1 [monitor CBC daily; lymphocyte nadir day -1]; DAY 0 TIL INFUSION: thaw bags bedside → infuse over 15-30 minutes × all bags; premedicate acetaminophen/diphenhydramine; HIGH-DOSE IL-2: ICU or step-down monitoring; aldesleukin 600,000 IU/kg Q8H IV starting 3-24h post-TIL; monitor for CLS [daily weight; urine output; BP Q2H; O2 saturation]; holds for hypotension [BP <90/60; vasopressors]; oliguria [<0.5 mL/kg/h]; pulmonary edema [O2 sat <90% RA]; grade 4 toxicity; maximum 6 doses; OCCUPATIONAL EHS CONCERN: lifileucel is NIOSH HD Cat 1 → antineoplastic handling protocols in pharmacy [class II BSC; PPE: double glove + gown + eye shield]; IL-2 aldesleukin also NIOSH HD Cat 1; EMPLOYEE: 41F MSK New York NY melanoma oncology attending C-144-01 lifileucel Amtagvi TIL high-dose IL-2 BLA 761408 10yr; EHS INSIGHT NULL: lifileucel → no record; NO CAS; NIOSH HD Category 1 absent; TIL infusion protocol absent; high-dose IL-2 Q8H ICU absent; capillary leak syndrome absent; lymphodepletion cyclophosphamide fludarabine absent).

Integrating Glyphward into Lifileucel AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every lifileucel (NO CAS NIOSH HD Cat 1) monitoring data ingestion point — before Cority at Iovance San Carlos CA, before VelocityEHS at Lonza Walkersville MD, and before EHS Insight at Memorial Sloan Kettering New York NY. Threshold 22: NO CONVENTIONAL CAS; NIOSH HD Category 1; NO OSHA PEL; NO ACGIH TLV; NO NIOSH REL [10 pts]; ONE-HUNDRED-TENTH MECHANISM CLASS — FIRST TIL ADOPTIVE CELL THERAPY EVER FDA APPROVED (BLA 761408 February 16 2024; non-engineered polyclonal autologous TILs; REP + high-dose IL-2; lymphodepletion; no gene transfer; C-144-01 ORR 31.5%; Iovance Biotherapeutics) [5 pts]; Iovance San Carlos CA + Lonza Walkersville MD + MSK New York NY [3 pts]; TIL mechanism absent; non-engineered polyclonal TCR absent; C-144-01 ORR 31.5% absent; high-dose IL-2 ICU absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_lifileucel(exposure_context: str) -> dict:
    """Scan lifileucel with one-hundred-tenth-class first-TIL-adoptive-cell-therapy context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": "NO_CAS_AUTOLOGOUS_LIVING_CELL_THERAPY",
                "exposure_context": exposure_context,
                "context": "one_hundred_tenth_class_first_til_adoptive_cell_therapy_ever_non_engineered_polyclonal_tcr_rep_high_dose_il2_lymphodepletion_cyclophosphamide_fludarabine_c_144_01_orr_31pct_iovance_bla_761408_feb_2024"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_tenth_class,
    #                    first_til_therapy, non_engineered_confirmed,
    #                    polyclonal_tcr_diversity, c_144_01_orr_31pct

if __name__ == "__main__":
    r = asyncio.run(scan_lifileucel(
        exposure_context="til_manufacturing_rep_high_dose_il2_cryopreservation_clinical_infusion_icu_monitoring"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_tenth_class': True,
    #  'first_til_therapy': True, 'non_engineered_confirmed': True,
    #  'polyclonal_tcr_diversity': True, 'c_144_01_orr_31pct': True}